Cereblon-Binding Small Molecules for Cross-Species T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunomodulatory drugs (IMiDs) like thalidomide face challenges in effectively targeting cereblon for enhanced T-cell activation and immunotherapy due to species-specific differences in substrate recognition and degradation, limiting their potency and selectivity in treating cancer and autoimmune diseases.
Innovation Solution
Development of small molecules that specifically target the cereblon E3 Ubiquitin Ligase binding moiety (CLM) to enhance T-cell function and immunotherapy by modulating IL-2 and IFNg production, using compounds represented by various structural formulas to induce target protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current IMiDs like thalidomide are used to target cereblon, then T-cell activation is enhanced, but species-specific differences in substrate recognition and degradation limit potency and selectivity
Solution Approach 1:
The patent modifies the chemical structure of IMiD compounds by introducing specific substitutions at the R1, R2, and R3 positions of the glutarimide ring, as well as modifications to the aromatic substituent. These structural parameter changes enhance the compounds' ability to bind cereblon across different species while maintaining selective T-cell activation, thereby resolving the contradiction between reliability and adaptability
Solution Approach 2:
The invention focuses on specific local modifications to the IMiD molecular structure, particularly at the R1, R2, and R3 positions, to optimize binding affinity for cereblon. By enhancing the local binding properties at these specific sites, the compounds achieve both reliable T-cell activation and reduced species-specific limitations
2Reliability
If cereblon is suppressed to induce T-cell activation, then anti-tumor immunity is restored, but abnormal limb development and teratogenic effects occur
Solution Approach 1:
The patent introduces specific local modifications to the IMiD structure, particularly substitutions at the R1 position (such as fluorine, chlorine, or bromine atoms) and modifications to the aromatic substituent. These localized changes enhance selective binding to cereblon in immune cells while reducing off-target effects that cause teratogenicity, thereby resolving the contradiction between anti-tumor immunity restoration and reduction of harmful teratogenic effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The small molecules enhance T-cell activation and immunotherapy efficacy, demonstrating potential in reducing tumor growth and treating autoimmune diseases and cancers by specifically targeting cereblon across different species.
Implementation Method 1
small molecules that specifically target the cereblon E3 Ubiquitin Ligase binding moiety (CLM) to enhance T-cell function and immunotherapy by modulating IL-2 and IFNg production, using compounds represented by various structural formulas to induce target protein degradation
Data Source
AI summary
Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.